The university of chicago
Center for Personalized Therapeutics
By making pharmacogenomic information prompt, accessible, and understandable for physicians, The Center for Personalized Therapeutics (CPT) leads the way in translating genomic discovery to improve care for patients.
Explore our program
In 2000 the first draft sequence of the human genome was released, and widespread use of techniques to implement and translate such genomic knowledge was slow to be adopted by the medical community. In 2009, the future leadership of the CPT felt that there was a critical mass of information regarding the association of individual genetic variability with drug-related adverse event and response outcomes and therefore established the Center.
The Center embarked on its first project in 2011, the 1200 Patients Project, which uses a preemptive medical system model that reduces the use of high risk medications. Later, the CPT established the ACCOuNT Project, the Impress Trial, the PhOCus Trial, and the PROTECT-Rx trial.
Research
CPT leads exceptional research on translational genomic discoveries and pharmocogenomics.
Projects
CPT conducts clinical trials in diverse medical fields, including perioperative, oncology, in-patient, out-patient, and beyond.
Training & Career
CPT offers opportunities for undergraduate, graduate, and post-doctoral trainees.
Collaboration
CPT partners with other departments and specialties to advance our understanding of the human genome.
Translating Genomic Discovery to Therapeutics
A word from the deputy director of Center for Personalized Therapeutics. Dr. Ratain talks about the program and how it is leading the field of clinical pharmacogenomics research and implementation.
📌Email Dr. Ratain for the welcoming video
Our faculty
Read more
Leader in personalized Therapeutics
We are a leading center in the field of personalized therapeutics, aiming to translate genomic discovery into results that will improve care for for patients. Our center has three completed and four ongoing projects. With 529 providers enrolled in our studies, CPT strives to make pharmacogenomic information available across multiple specialties.
Total providers enrolled in the US
Projects
Providers enrolled in the ACCOuNT Project
Providers enrolled in the ImPreSS Trial
OUr Goal
One of the key goals of the Center is to develop systems for efficient collection, storage, and clinical application of genetic data and to train physicians in the use of personalized genetic information as tools in patient care. We hope this can help identify the patients most likely to respond to, or be harmed by, specific therapies.
Current CPT research focuses on the evaluation and application of pharmacogenomics information in the context of clinical trials at all phases of drug development.
In the near future, the Center plans to expand the availability of pre-emptive clinical testing for use in additional patient populations at a variety of institutions around the country. The ultimate goal of the Center is to develop innovative, personalized and effective therapies for all patients, and promote the use of genetic testing to develop personalized treatment plans.
📍Images of lab here will be great.
Our Latest Projects
The Center of Personalized Therapeutics has completed three projects, including the 1200 Patients Project, ACCoUNT Project, ImPreSS Trial and PhOCus Trial. CPT is working on Chablis Project, PTC Project, Diversity Studies, and Pharmacoeconomics. 📌Maybe make this sound a little bit more exiting?
The 1200 Patients Project
Piloting the use of pharmacogenomics in routine medical care.
ACCOuNT Project
Examining pharmacogenomic implementation in the context of minority health disparities.
PhOCus Trial
Studying pharmacogenomic testing in Oncology care
The Impress Trial
Implementing pharmacogenomic testing in anesthesia and perioperative medicine.
CHABLIS Project
Longitudinal research to promote healthy aging behaviors.
PTC Project
An effort to expand access to personalized therapeutic consultations to high risk patients.
Diversity Studies
Consult Dr. Loren Saulsberry or Andre Hall (CRC)
Pharmacoeconomics
Addressing the importance of optimal dosing of anticancer agents.
Exceptional Training & Career opportunities
From Our Faculty
📍This will be some quotes from faculty, trainees, professors, get their quotes blah blah. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit laborum. Sed ut perspiciatis unde omnis. 📍
“There are many variations of passages of Lorem Ipsum available, but the majority have suffered alteration by injected humour.”📍
“There are many variations of passages of Lorem Ipsum available, but the majority have suffered alteration by injected humour.” 📍
“There are many variations of passages of Lorem Ipsum available, but the majority have suffered alteration by injected humour.”📍
“There are many variations of passages of Lorem Ipsum available, but the majority have suffered alteration by injected humour.” 📍